Skip to Main content Skip to Navigation
Journal articles

ABCL-040: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent Bruton's Tyrosine Kinase Inhibitor in Previously Treated Mantle Cell Lymphoma and Other Non-Hodgkin Lymphomas: Phase 1/2 BRUIN Study Results

Jonathon Cohen 1 Nirav Shah 2 Alvaro Alencar 3 James Gerson 4 Manish Patel 5 Bita Fahkri 6 Wojciech Jurczak 7 Xuan Tan 8 Katharine Lewis 8 Timothy Fenske 2 Catherine Coombs 9 Ian Flinn 5 David Lewis 10 Steven Le Gouill 11, 12 M Lia Palomba 13 Jennifer Woyach 14 John Pagel 15 Nicole Lamanna 16 Minal Barve 17 Paolo Ghia 18 Toby Eyre 19 Ming Yin 20 Binoj Nair 20 Donald Tsai 20 Nora Ku 20 Anthony Mato 13 Chan Cheah 8 Michael Wang 21 
Document type :
Journal articles
Complete list of metadata

https://www.hal.inserm.fr/inserm-03546766
Contributor : Elizabeth Bernardo Connect in order to contact the contributor
Submitted on : Friday, January 28, 2022 - 10:19:43 AM
Last modification on : Wednesday, April 27, 2022 - 3:59:51 AM

Identifiers

Citation

Jonathon Cohen, Nirav Shah, Alvaro Alencar, James Gerson, Manish Patel, et al.. ABCL-040: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent Bruton's Tyrosine Kinase Inhibitor in Previously Treated Mantle Cell Lymphoma and Other Non-Hodgkin Lymphomas: Phase 1/2 BRUIN Study Results. Clinical Lymphoma, Myeloma & Leukemia, Elsevier, 2021, 21, pp.S378-S379. ⟨10.1016/S2152-2650(21)01863-2⟩. ⟨inserm-03546766⟩

Share

Metrics

Record views

8